By Stephen Nakrosis
BioLingus (Cayman) Ltd. filed for an initial public offering Friday with the U.S. Securities and Exchange Commission.
The company said its subsidiaries are developing sublingual, or under the tongue, methods to deliver peptides and proteins, such as insulin. “Many of the more effective drugs to treat diabetes and obesity are ‘biologics’, the vast majority of which currently have to be injected,” the company said.
BioLingus (Cayman) is a holding company whose main business operations are conducted through subsidiaries in Switzerland and, “to a lesser extent, HK SAR, the People’s Republic of China and Australia,” the company said
The company also said it expects to offer 3 million ordinary shares priced between $15 a share and $16 a share.
BioLingus (Cayman) said it intends to apply to list on the Nasdaq Capital Market under the symbol SUBL.
Univest Securities is listed as the offering’s underwriter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
Read the full article here